The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

<b>Background:</b> Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to metabolic syndrome, type 2 diabetes, and obesity. This study investigates the relationship between physical capacity, assessed by the Global Physical Capacity Score (GPCS), and MASLD-related parameters, including hepatic steatosis (CAP score), insulin resistance (HOMA-IR), and body mass index (BMI). <b>Methods:</b> A cross-sectional analysis was performed on 204 individuals with MASLD (mean age: 50 years; 57.6% males). Participants underwent physical tests to determine their GPCS. Hepatic steatosis was assessed using FibroScan® (Echosens, Paris, France), and metabolic markers were collected from fasting blood samples. Statistical analyses included linear and logistic regression models adjusted for potential confounders. <b>Results:</b> A higher GPCS was inversely associated with CAP (β = -5.30; <i>p</i> < 0.05), HOMA-IR (β = -0.28; <i>p</i> < 0.001), and BMI (β = -0.96; <i>p</i> < 0.001). Logistic regression analysis confirmed a lower risk of severe hepatic steatosis (OR = 0.44; <i>p</i> < 0.05), obesity (OR = 0.39; <i>p</i> < 0.05), and insulin resistance (OR = 0.32; <i>p</i> < 0.001) in individuals with higher GPCS values. <b>Conclusions:</b> The GPCS may indicate MASLD severity and reflect metabolic and hepatic health. Our findings support the promotion of physical activity and suggest a potential role for GPCS in risk stratification and personalized interventions for patients with MASLD.